I-Shark Cartilage

Umxholo

• Ngokuqinisekileyo ayisebenzi ...
• Akukho bungqina baneleyo bokulinganisa ukusebenza ...
• Amanyathelo okhuseleko kunye nezilumkiso:

I-Shark cartilage (izicwili ezomeleleyo ezomeleleyo ezixhasa, njengoko ithambo lenza) esetyenziselwa amayeza avela ikakhulu kookrebe ababanjwe kuLwandlekazi lwePasifiki. Iindidi ezininzi zezicatshulwa zenziwe kwi-shark cartilage kubandakanya i-squalamine lactate, AE-941, kunye ne-U-995.

I-shark cartilage isetyenziswa kakhulu kumhlaza. I-shark cartilage ikwasetyenziselwa i-osteoarthritis, i-plaque psoriasis, ukulahleka kombono okuhambelana nobudala, ukuphilisa amanxeba, ukonakalisa i-retina yamehlo ngenxa yesifo seswekile, kunye nokudumba kwamathumbu (i-enteritis).

Abanye abantu bathambisa i-shark cartilage ngqo kulusu lwe-arthritis kunye ne-psoriasis.

Abanye abantu bathambisa u-shark cartilage kwi-rectum yomhlaza.

Amayeza endalo aVimba weDatha Ukusebenza kwexabiso ngokusekwe kubungqina besayensi ngokwala manqanaba alandelayo: Ukusebenza, ukusebenza ngokukuko, okunokwenzeka ukuba kusebenze, okungenzeka kungasebenzi, kunokwenzeka ukungasebenzi, ukungasebenzi, kunye nobungqina obungonelanga bokulinganisa.

Ukulinganiswa kokusebenza kwe IKATALA LIKA SHARK zezi zilandelayo:

Ngokuqinisekileyo ayisebenzi ...

• Umhlaza. Uninzi lophando lubonisa ukuba ukuthatha u-shark cartilage ngomlomo akuncedi nto kubantu abaphucukileyo, ngaphambili abanyangwa umhlaza webele, ikholoni, imiphunga, iprostate, okanye ingqondo. Kukwabonakala ngathi aluncedo kubantu abane-advanced, ngaphambili eyayinyangwa engeyiyo iHodgkin's lymphoma. I-shark cartilage ayifundiswanga kubantu abanomhlaza ongaphantsi.

Akukho bungqina baneleyo bokulinganisa ukusebenza ...

• Isisu somhlaza esibizwa ngokuba yiKaposi sarcoma. Kukho iingxelo zokuba ukusebenzisa intyatyambo yookrebe kulusu kunokunciphisa amathumba abizwa ngokuba yiKaposi sarcoma. Ezi tumors zixhaphake kakhulu kubantu abane-HIV.
• Osteoarthritis. Xa isetyenziswa kulusu, iimveliso eziqulathe u-shark cartilage ngokudibeneyo kunye nezinye izithako zichaza ukunciphisa iimpawu zesifo samathambo. Nangona kunjalo, nakuphi na ukukhululeka kweempawu kunokwenzeka ngenxa yesithako se-camphor hayi ezinye izithako. Ukongeza, akukho phando lubonisa ukuba u-shark cartilage ufunxwe eluswini.
• Unyango. Uphando lwakwangoko kubantu abane-plaque psoriasis lubonisa ukuba isicatshulwa esithile sikakrebe (i-AE-941) siphucula ukubonakala kwamacwecwe kwaye sinciphise ukurhawuzelela xa sithathwa ngomlomo okanye sisetyenziswa kulusu.
• Uhlobo lomhlaza wezintso obizwa ngokuba yi-renal cell carcinoma. Ukuthatha isicatshulwa esithile se-shark cartilage (AE-941) ngomlomo kunokunyusa ukusinda kwizigulana ezine-renal cell carcinoma.
• Ukuphulukana nombono ngokunxulumene nobudala.
• Ukuphilisa amanxeba.
• Ezinye iimeko.

Ubungqina obungakumbi buyafuneka ukukala u-shark cartilage kwezi zinto zisetyenziswayo.

I-shark cartilage inokuthintela ukukhula kwemithambo yegazi emitsha efunekayo ukuze umhlaza ukhule. Inokuthintela nokukhula kwemithambo yegazi kwizilonda ze-psoriasis. Oku kunokunceda ukuphilisa la manxeba.

I-shark cartilage yile UKHUSELEKO OLUNOKWENZEKA kubantu abaninzi xa bethathwe ngomlomo ukuya kuthi ga kwiinyanga ezingama-40 okanye xa befaka ulusu kangangeeveki ezisi-8.

Ingabangela ukungcamla okungalunganga emlonyeni, isicaphucaphu, ukugabha, ukukhathazeka esiswini, ukuqhina, uxinzelelo lwegazi, isiyezi, iswekile ephezulu yegazi, amanqanaba aphezulu e-calcium, ubuthathaka kunye nokudinwa. Isenokubangela ukungasebenzi kwesibindi. Ezinye iimveliso zinevumba elibi kunye nencasa.

Amanyathelo okhuseleko kunye nezilumkiso:

Ukukhulelwa kunye nokuncancisa: Akukho lwazi lwaneleyo malunga nokukhuseleka kokuthatha u-shark cartilage ukuba ukhulelwe okanye uncancisa. Hlala kwicala elikhuselekileyo kwaye uphephe ukusetyenziswa.

"Izifo ezisebenza ngokuzenzekelayo" ezifana ne-multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), isifo samathambo (RA), okanye ezinye iimekoI-Shark cartilage inokubangela ukuba amajoni omzimba asebenze ngakumbi. Oku kunokunyusa iimpawu zezifo ezizimele. Ukuba unayo enye yezi meko, kungcono ungasebenzisi i-shark cartilage.

Amanqanaba aphezulu e-calcium (hypercalcemia): I-shark cartilage inokunyusa amanqanaba e-calcium, ngoko ayifanele isetyenziswe ngabantu abanamaqondo e-calcium asele aphezulu kakhulu.

Iphakathi

Lumka ngale nhlanganisela.

Amayeza anciphisa amajoni omzimba (i-Immunosuppressants)

I-shark cartilage inokunyusa amajoni omzimba. Ngokwandisa amajoni omzimba, u-shark cartilage unokunciphisa ukusebenza kwamayeza anciphisa amajoni omzimba.

Amanye amayeza anciphisa amajoni omzimba abandakanya i-azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf ), Sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids) kunye nabanye.

Ikhalsiyam

I-shark cartilage inokuphakamisa amanqanaba e-calcium. Kukho inkxalabo yokuba ukuyisebenzisa kunye nezongezo zekhalsiyam kunokwenza amanqanaba e-calcium aphezulu kakhulu.

Incindi yeziqhamo

Ijusi yeziqhamo enesidisi efana neorenji, iapile, iidiliya, okanye itumato, ingathoba amandla ookrebe njengoko imizuzu idlula. Ukuba intyatyambo yookrebe yongezwa kwincindi yeziqhamo, kufuneka yongezwe kanye phambi kokuyisebenzisa.

Idosi efanelekileyo ye-shark cartilage ixhomekeke kwizinto ezininzi ezinje ngeminyaka yomsebenzisi, impilo, kunye nezinye iimeko. Ngeli xesha akukho lwazi lwaneleyo lwesayensi ukumisela uluhlu olufanelekileyo lweedosi zekreyiti ye-shark. Gcina ukhumbula ukuba iimveliso zendalo azisoloko zikhuselekile kwaye iidosi zibalulekile. Qiniseka ukuba ulandela umkhombandlela ofanelekileyo kwiilebheli zemveliso kwaye uqhagamshelane nosokhemesti okanye ugqirha okanye olunye uqeqesho kwezempilo ngaphambi kokusebenzisa.

AE-941, Cartilage de Requin, Cartilage de Requin du Pacifique, Cartilago de Tiburon, Collagène Marin, Extrait de Cartilage de Requin, Liquide de Cartilage Marin, Marine Collagen, Marine Liquid Cartilage, MSI-1256F, Neovastat, Pacific Shark Cartilage, Poudre de Cartilage de Requin, Shark Cartilage Powder, Shark Cartilage Extract, Sphyrna lewini, Squalus acanthias.

Ukuze ufunde okungakumbi malunga nokubhalwa kweli nqaku, nceda ubone Amayeza endalo aVimba weDatha indlela yokusebenza.

1. Merly L, Smith SL. Iipropathi zokuchasana ne-shark cartilage supplement. Immunopharmacol Immunotoxicol. Ngo-2015; 37: 140-7. Jonga i-abstract.
2. Sakai S, Otake E, Toida T, Goda Y. Ukuchongwa kwemvelaphi ye chondroitin sulphate "kukutya kwezempilo". UChem Pharm Bull (eTokyo). Ngo-2007; 55: 299-303. Jonga i-abstract.
3. Ukudityaniswa kweBhodi yokuHlola, eNye indlela, kunye neBhodi yokuHlela yokuNyanga. I-Cartilage (Bovine and Shark) (PDQ®): Inguqulelo yezeMpilo. Isishwankathelo soLwazi ngomhlaza se-PDQ [kwi-Intanethi]. I-Bethesda (MD): IZiko leSizwe loMhlaza (i-US); 2002. 2016 Jul 21. Jonga i-abstract.
4. Isicatshulwa seGoldman E. Shark intlala sizamile njengonyango lwenoveli ye-psoriasis. Ulusu Zonke Iindaba 1998; 29: 14.
5. Ukutya kunye noLawulo lweziyobisi. I-FDA ithatha amanyathelo ngokuchasene nokuthengisa ngokuqinileyo iziyobisi ezingavunyelwanga. Iphepha le-FDA lentetho (ngoDisemba 10, 1999)
6. Umgaqo W kunye noMilner M. Ukuthelekiswa kwe-shark cartilage kunye ne-bovine cartilage. I-Townsend Lett 1996; 153: 40-42.
7. UZhuang, L, Wang, B, Shivji, G, kunye no-al. I-AE-941, inoveli inhibitor ye-angiogenesis inefuthe elibonakalayo lokuchasana nokudumba kunxibelelwano lwe-hypersensitivity. J Invest Derm 1997; 108: 633.
8. I-Turcotte P. Isigaba sokufunda sokwanda kwenqanaba le-AE-941, iarhente ye-antiangiogenic, kwisigulana esihambelana nobudala be-macular. INgqungquthela yoMbutho weRetina (eHawaii, nge-2 kaDisemba ngo-1999).
9. Ukwahlula i-DN. I-Angiogenesis antagonist njengonyango lwe-psoriasis: Isigaba I iziphumo zovavanyo lweklinikhi nge-AE-941. I-American Academy yeNgqungquthela yeDermatology, eNew Orleans, eLouisana, ngoMatshi 19-24, 1999.
10. I-Aeterna Laboratories Inc. Isigaba III sophando olungenamkhethe lwe-AE-941 (Neovastat; Shark Cartilage Extract) kwizigulana ezine-metastatic renal cell carcinoma refractory to immunotherapy. 2001.
11. U-Escudier, B, Patenaude, F, Bukowski, R, kunye no-al. Isizathu sesigaba sesithathu sovavanyo lweklinikhi kunye ne-AE-941 (Neovastat (R)) kwizigulana ze-renast cell ze-carcinoma ezichasayo kwi-immunotherapy. UAnn Oncol 2000; 11 (ongezelele 4): 143-144.
12. UDupont E, uAlaoui-Jamali M, uWang T, kunye no-al. Umsebenzi we-Angiostatic kunye ne-antitumoral ye-AE-941 (Neovastat), iqhekeza leemolekyuli elivela kwi-shark cartilage. Iinkqubo zoMbutho waseMelika woPhando lweCancer 1997; 38: 227.
13. UShimizu-Suganuma, Masum, Mwanatambwe, Milanga, Iida, Kazum, et al. Iziphumo zekreyiki ye-shark kwi-tumor ukukhula kunye nexesha lokusinda kwi-vivo (meeting abstract). U-Proc Annu udibana ne-Soc Clin Oncol 1999; 18: A1760.
14. Ongaziwayo. Umsebenzi we-Angiostatic kunye ne-antitumoral ye-AE-941 (neovastat-R), iqhezu leemolekyuli ezivela kwi-shark cartilage (intlanganiso ye-abstract). U-Proc Annu udibana ne-Assoc Cancer Res 1997; 38: A1530.
15. ICataldi, JM kunye neOsborne, DL. Iziphumo zekreyiki ye-shark kwi-mammary tumor neovascularization kwi-vivo kunye nokwanda kweseli kwi-vitro (intlanganiso ye-abstract). Ijenali yeFASEB 1995; 9: A135.
16. UJamali MA, uRiviere P, uFalardeau A, kunye no-al. Iziphumo ze-AE-941 (Neovastat), i-angiogenesis inhibitor, kwimodeli ye-metastatic ka-Lewis lung carcinoma, ukusebenza ngempumelelo, ukuthintela ubuthi kunye nokusinda. Iiklinikhi zityala iMed 1998; (suppl): S16.
17. I-Saad F, i-Klotz L, i-Babaian R, i-Lacombe L, i-Champagne P, kunye ne-Dupont E. Isigaba se-I / II sokuvavanywa kwi-AE-941 (Neovastat) kwizigulana ezinomhlaza wesifo seprostate (i-expression abstract). Intlanganiso yoNyaka yoMbutho wase-Canada we-Urological (ngoJuni 24-27, 2001).
18. URosenbluth, uRJ, uJennis, uAA, uCantwell, uS, kunye no-al. I-Oral shark cartilage kunyango lwezigulana ezinezicubu zobuchopho eziphambili. Isifundo somqhubi wenqanaba II (intlanganiso engabonakaliyo). U-Proc Annu udibana ne-Soc Clin Oncol 1999; 18: A554.
19. UDupont E, uSavard RE, uJourdain C, uJuneau C, uThibodeau A, uRoss N, et al. Iipropathi ze-Antiangiogenic zenoveli ye-shark cartilage extract: indima enokubakho kunyango lwe-psoriasis. J Cutan Med ngo-1998; 2: 146-152.
20. Umgaqo we-IW kunye ne-Contreras E.Izinga eliphezulu le-bioactivity (ukunciphisa ubungakanani besisu) kubonwe kwizigulana ezinomhlaza eziqhubele phambili ziphathwa ngezinto zekreyiti. J Naturopath Med 1992; 3: 86-88.
21. UWilson JL. Imixholo ye-shark cartilage yoyisa i-psoriasis. Enye into yeCandelo le-Ther 2000; 6: 291.
22. URiviere M, Latreille J, kunye no Falardeau P. AE-941 (Neovastat), isithintelo se-angiogenesis: iziphumo zesilingo somhlaza wesigaba se-I / II. ICancer Invest 1999; 17 (suppl 1): 16-17.
23. Milner M. Isikhokelo sokusetyenziswa kwe-shark cartilage kunyango lwe-arthritis kunye nezinye izifo ezidibeneyo zokudumba. Amer Chiropractor 1999; 21: 40-42.
24. Leitner SP, Rothkopf MM, Haverstick DD, kunye et al. Izifundo ezibini zesigaba sesibini somlomo owomileyo we-shark cartilage powder (i-SCP) kwizigulana ezinesifuba se-metastatic okanye somhlaza webala le-Prostate elichasayo kunyango oluqhelekileyo. Amer Soc Clin Oncol 1998; 17: A240.
25. U-Evans WK, uLatreille J, uBatist G, kunye no-al. I-AE-941, i-inhibitor ye-angiogenesis: ingqiqo yophuhliso ngokudibanisa ne-induction chemotherapy / i-radiotherapy kwizigulana ezinomhlaza womhlaza wamaphaphu ongekho mncinci (NSCLC). Amaphepha aNziweyo ngo-1999; S250.
26. URiviere M, Falardeau P, Latreille J, kunye et al. Isigaba I / II somhlaza wemiphunga kuvavanyo lweziphumo nge-AE-941 (Neovastat ®) inhibitor ye-angiogenesis. Iiklinikhi yokuTyala iMed (ukongeza) ngo-1998; S14.
27. URiviere M, uAlaoui-Jamali M, Falardeau P, kunye no-al. I-Neovastat: isithintelo se-angiogenesis kunye nomsebenzi onxamnye nomhlaza. Inkqubo ye-Amer Assoc Cancer Res 1998; 39: 46.
28. Akukho babhali. Uvavanyo lweklinikhi lwe-Neovastat. 2001;
29. IAeterna Laboratories Inc. Uphononongo lweSigaba II se-AE-941 (Neovastat; Shark Cartilage) kwizigulana ezinokubuyela umva kwangoko okanye ukuphindaphinda okuninzi kwe-myeloma. 2001. Inombolo yoNxibelelwano yoLwazi 1-888-349-3232.
30. UFelzenszwalb, I., Pelielo de Mattos, J. C., Bernardo-Filho, M., noCaldeira-de-Araujo, A. Shark intlala enamalungiselelo: ukukhuselwa kwiintlobo zeoksijini ezisebenzayo. Ukutya kweChem Toxicol 1998; 36: 1079-1084. Jonga i-abstract.
31. ICoppes, M.J, Anderson, R. A., Egeler, R. M., kunye noWolff, J. E. Olunye unyango lwezonyango lomhlaza wabantwana. N Engl. J Med 9-17-1998; 339: 846-847. Jonga i-abstract.
32. UDavis, PF, He, Y., Furneaux, R. H., Johnston, P. S., Ruger, B. M., kunye no-Slim, G. C. Ukuthintela i-angiogenesis ngokufakwa ngomlomo kwe-cartilage ye-shark kwimodeli yempuku. IMicrosoftvasc. 1997; 54: 178-182. Jonga i-abstract.
33. UMcGuire, T. R., Kazakoff, P. W., Hoie, E. B., kunye noFienhold, M. A. Umsebenzi wokulwa ne-cartilage ye-shark kunye nangaphandle kwe-tumor necrosis factor-alpha kwi-veil endothelium yomntu. I-Pharmacotherapy 1996; 16: 237-244. Jonga i-abstract.
34. Kuettner, K. E. kunye noPauli, B. U. Uthintelo lwe-neovascularization yento ye-cartilage. Ciba ifunyenwe. Ngo-1983; 100: 163-173.Jonga i-abstract.
35. U-Lee, A. kunye noLanger, R. I-Shark cartilage iqulethe inhibitors zesisu angiogenesis. Inzululwazi 9-16-1983; 221: 1185-1187. Jonga i-abstract.
36. Korman, D. B. [Iipropathi ze-antiangiogenic kunye ne-antitumor of cartilage]. Vopr.I-Onkol. Ngo-2012; 58: 717-726. Jonga i-abstract.
37. UPatra, D. kunye noSandell, uL. J. Antiangiogenic kunye ne-anticancer molecule kwi-cartilage. Ingcali, uMfu Mol. Med 2012; 14: e10. Jonga i-abstract.
38. de Mejia, E. G. kunye noDia, V. P. Indima yeeproteni ze-nutraceutical kunye neepeptides kwi-apoptosis, angiogenesis, kunye ne-metastasis yeeseli zomhlaza. Umhlaza weMetastasis Rev 2010; 29: 511-528. Jonga i-abstract.
39. Bargahi, A., Hassan, Z. M., Rabbani, A., Langroudi, L., Noori, S.H, kunye noSafari, E. Iziphumo zekreyiti ye-shark evela kwiprotheyini yomsebenzi weeseli ze-NK. I-Immunopharmacol kunye neImmunotoxicol. Ngo-2011; 33: 403-409. Jonga i-abstract.
40. U-Lee, S.Y. kunye noChung, S. M. Neovastat (AE-941) uthintela ukuvuvukala komoya ngokusebenzisa i-VEGF kunye ne-HIF-2 alpha. IVascul. Pharmacol 2007; 47 (5-6): 313-318. Jonga i-abstract.
41. I-Pearson, W., Orth, M. W., Karrow, N. A., Maclusky, N. J., kunye noLindinger, M. I. Iziphumo ezichasene nokuvuvukala kunye ne-chondroprotective ye-nutraceuticals evela kwi-Sasha's Blend kwimodeli yokuqhekeka kwe-cartilage. Ukutya kweMol Nutrut Res 2007; 51: 1020-1030. Jonga i-abstract.
42. UKim, S., de, A., V, Bouajila, J., Dias, AG, Cyrino, FZ, Bouskela, E., Costa, PR, kunye noNepveu, F. Alpha-phenyl-N-tert-butyl nitrone ( I-PBN) Iziphumo ezivela kwimvelaphi: isenzo kunye nokukhusela isenzo somonakalo kwimicrovascular ebangelwa yi-ischemia / reperfusion. I-Bioorg. I-Med Chem 5-15-2007; 15: 3572-3578. Jonga i-abstract.
43. Merly, L., Simjee, S., kunye noSmith, S. L. Ukwenziwa kwee-cytokines ezivuthayo zizicatshulwa ze-cartilage. Int Immunopharmacol. Ngo-2007; 7: 383-391. Jonga i-abstract.
44. UMoses, M. A., Sudhalter, J., kunye noLanger, R. Ukuchongwa kwe-inhibitor ye-neovascularization kwi-cartilage. Inzululwazi 6-15-1990; 248: 1408-1410. Jonga i-abstract.
45. URatel, D., Glazier, G., Provencal, M., Boivin, D., Beaulieu, E., Gingras, D., noBeliveau, R. I-enzyme esebenza ngokuthe ngqo kwi-fibrinolytic enzyme kwi-shark cartilage extract: ukuphazamiseka. Itromb. 2005; 115 (1-2): 143-152. Jonga i-abstract.
46. UGingras, D., Labelle, D., Nyalendo, C., Boivin, D., Demeule, M., Barthomeuf, C., noBeliveau, R.Iarhente ye-antiangiogenic Neovastat (AE-941) ivuselela umsebenzi we-activator ye-plasminogen. Tyala iziyobisi iziyobisi 2004; 22: 17-26. Jonga i-abstract.
47. I-Latreille, J., Batist, G., Laberge, F., Champagne, P., Croteau, D., Falardeau, P., Levinton, C., Hariton, C., Evans, WK, kunye neDupont, E. Phase Uvavanyo lwe-I / II lokhuseleko kunye nokusebenza kwe-AE-941 (Neovastat) kunyango lomhlaza wamaphaphu ongaqhelekanga. Umhlaza weClin Lung Cancer 2003; 4: 231-236. Jonga i-abstract.
48. I-Bukowski, R. M. AE-941, ikhompawundi esebenzayo ye-antiangiogenic: izilingo kwi-renal cell carcinoma. Ingcali.Opin.Uphando.Iziyobisi 2003; 12: 1403-1411. Jonga i-abstract.
49. UJagannath, S., Champagne, P., Hariton, C., kunye noDupont, E. Neovastat kwi-myeloma emininzi. I-Eur. J. Haematol. Ngo-2003; 70: 267-268. Jonga i-abstract.
50. I-FDA inika imeko yeenkedama kunye neziyobisi kwi-Aeterna's Neovastat yomhlaza wezintso. Ingcali. Rev Anticancer Ther 2002; 2: 618. Jonga i-abstract.
51. Dupont, E., Falardeau, P., Mousa, SA, Dimitriadou, V., Pepin, MC, Wang, T., kunye no-Alaoui-Jamali, MA Antiangiogenic kunye neempawu zokulwa ne-antimetastatic zeNeovastat (AE-941), isicatshulwa esisebenza ngomlomo. ivela kwilungu le-cartilage. Iiklinikhi Exp Metastasis 2002; 19: 145-153. Jonga i-abstract.
52. IBeliveau, R., Gingras, D., Kruger, EA, Lamy, S., Sirois, P., Simard, B., Sirois, MG, Tranqui, L., Baffert, F., Beaulieu, E., Dimitriadou, V., Pepin, MC, Courjal, F., Ricard, I., Poyet, P., Falardeau, P., Figg, WD, kunye noDupont, E. Ummeli we-Antiangiogenic Neovastat (AE-941) Uthintela iVascular Endothelial Growth Factor. Iziphumo zeBioloji. Umhlaza weklinikhi Res 2002; 8: 1242-1250. Jonga i-abstract.
53. UWeber, M.H, Lee, J., kunye no-Orr, F. W. Iziphumo zeNeovastat (AE-941) kwimodeli yovavanyo lwethambo leemastastatic. Int J Oncol 2002; 20: 299-303. Jonga i-abstract.
54. IBarber, R., Delahunt, B., Grebe, S. K., Davis, P. F., Thornton, A., kunye no-Slim, G. C. Oral shark cartilage ayiphelisi i-carcinogenesis kodwa iyalibazisa ukuqhubela phambili kwesisu kwimodeli ye-murine. I-Anticancer Res 2001; 21 (2A): 1065-1069. Jonga i-abstract.
55. UGonzalez, RP, Soares, FS, Farias, RF, Pessoa, C., Leyva, A., Barros Viana, GS, kunye neMoraes, MO Ukubonakaliswa kwempembelelo yothintelo lomlomo we-shark cartilage kwizinto ezisisiseko zokukhula kwe-fibroblast factor-induced angiogenesis kumvundla. yekona. Biol.Umveliso.Inkunzi yenkomo. 2001; 24: 151-154. Jonga i-abstract.
56. Brem, H. kunye noFolkman, J. Ukuthintela i-tumor angiogenesis ekulamla ngentlala. J Exp uMed 2-1-1975; 141: 427-439 (PubMed) (Umnqamlezo) Jonga i-abstract.
57. Koch, A. E. Indima ye-angiogenesis kwisifo samathambo: uphuhliso lwamva nje. UAnn Rheum. Dis. 2000; 59 iSuppl 1: i65-i71. Jonga i-abstract.
58. Iintetho, K. L. kunye noHarris, A. L. Isimo sangoku sezinto ze-antiangiogenic. UBr J Haematol. Ngo-2000; 109: 477-489. Jonga i-abstract.
59. UMorris, G. M., Coderre, J. A., Micca, P. L., Lombardo, D.T, kunye noHopewell, J. W. Boron neutron unyango lokubamba i-rat 9L gliosarcoma: kuvavanyo lwempembelelo ye-shark cartilage. Br J Radiol. Ngo-2000; 73: 429-434. Jonga i-abstract.
60. URenckens, C.N kunye noVan Dam, F. S. [Ingxowa mali kazwelonke yomhlaza (iKoningin Wilhelmina Fonds) kunye neHoutsmuller-unyango lomhlaza]. I-Ned, iTijdschr, iGeneeskd. 7-3-1999; 143: 1431-1433. Jonga i-abstract.
61. UMoses, MA, Wiederschain, D., Wu, I., Fernandez, CA, Ghazizadeh, V., Lane, WS, Flynn, E., Sytkowski, A., Tao, T., kunye noLanger, R. Troponin ndingu zikhona kwi-cartilage yomntu kwaye zithintela i-angiogenesis. Inkqubo Natl Acad.Sci.U.S. 3-16-1999; 96: 2645-2650. Jonga i-abstract.
62. UMoller HJ, uMoller-Pedersen T, uDamsgaard TE kunye noPoulsen JH. Ukubonakaliswa kwe-immunogenic keratin sulphate kwintengiso ye-chondroitin 6-sulphate evela kwi-shark cartilage. Iziphumo zeemvavanyo ze-ELISA. Iiklinikhi zeChim Acta 1995; 236: 195-204. Jonga i-abstract.
63. ULu C, uLee JJ, uKomaki R, et al. I-Chemoradiotherapy kunye okanye ngaphandle kwe-AE-941 kwisigaba III somhlaza wesifo somhlaza wamaphaphu: isilingo sesigaba III esingahleliwe. J Natl Umhlaza Inst 2010; 102: 1-7. Jonga i-abstract.
64. ILoprinzi CL, uLevitt R, uBarton DL, et al. Uvavanyo lwe-shark cartilage kwizigulana ezinomhlaza ophambili: ulingo lweQela loNyango loMhlaza kuMantla. Umhlaza 2005; 104: 176-82. Jonga i-abstract.
65. Batist G, Patenaude F, Champagne P, et al. I-Neovastat (AE-941) kwizigulana ze-renal cell carcinoma: ingxelo yesigaba sesibini sokulinga ngamanqanaba amabini edosi. UAnn Oncol 2002; 13: 1259-63 .. Jonga i-abstract.
66. ISauder DN, iDekoven J, iChampagne P, et al. I-Neovastat (AE-941), i-inhibitor ye-angiogenesis: Isigaba esingahleliwe se-I / II sonyango siphumo kwizigulana ezine-plaque psoriasis. Ndiyi-Acad Dermatol 2002; 47: 535-41. Jonga i-abstract.
67. UGingras D, uRenaud A, uMousseau N, et al. Ukuchaneka I-Matrix proteinase inhibition yi-AE-941, ikhompawundi esebenzayo ye-antiangiogenic. I-Anticancer Res 2001; 21: 145-55 .. Jonga i-abstract.
68. UFalardeau P, uChampagne P, uPoyet P, et al. I-Neovastat, iziyobisi ezenziwayo ezibandakanya imisebenzi emininzi, kwinqanaba lesithathu lezilingo zonyango. Isemina i-Oncol 2001; 28: 620-5 .. Jonga i-abstract.
69. UBoivin D, uGendron S, uBeaulieu E, et al. Iarhente ye-antiangiogenic Neovastat (AE-941) inducus endothelial cell apoptosis. Umhlaza womhlaza Ther 2002; 1: 795-802 .. Jonga i-abstract.
70. U-Cohen M, u-Wolfe R, u-Mai T, u-Lewis D. Uvavanyo olungahleliwe, oluyimfama, olulawulwa yi-placebo lwekhrimu ye-cream ene-glucosamine sulfate, i-chondroitin sulphate, kunye ne-camphor ye-osteoarthritis emadolweni. J Rheumatol 2003; 30: 523-8 .. Jonga i-abstract.
71. UMeyi B, Kuntz HD, uKieser M, uKohler S. Ukusebenza kweoyile yepepermint / ioyile edityanisiweyo kwi-non-ulcer dyspepsia. IArzneimittelforschung 1996; 46: 1149-53. Jonga i-abstract.
72. Anon. I-AEterna ibhengeza ukuqala kokubhaliswa kwesigulana kwi-NIH-exhaswe inqanaba lesi-III kuvavanyo lweklinikhi lwe-AE-941 / Neovastat kunyango lomhlaza wemiphunga. Ukukhutshwa kweendaba kwiAeterna 2000 ngoMeyi 17.
73. Sheu JR, Fu CC, Tsai ML, Chung WJ. Iziphumo ze-U-995, i-angiogenesis inhibitor enamandla e-shark cartilage, kwi-anti-angiogenesis kunye ne-anti-tumor. I-Anticancer Res 1998; 18: 4435-41. Jonga i-abstract.
74. UFontenele JB, Viana GS, Xavier-Filho J, de-Alencar JW. Umsebenzi olwa ne-anti-inflammatory kunye ne-analgesic yeqhekeza elinyibilikayo emanzini ukusuka kwi-shark cartilage. IBraz J Med Biol Res 1996; 29: 643-6. Jonga i-abstract.
75. IFontenele JB, Araujo GB, de Alencar JW, Viana GS. Iziphumo ze-analgesic kunye ne-anti-inflammatory zoshaka we-shark zibangelwa yimolekyuli ye-peptide kwaye zixhomekeke kwinkqubo ye-nitric oxide (NO). I-Biol Pharm Bull 1997; 20: 1151-4. Jonga i-abstract.
76. I-Gomes EM, i-Souto PR, i-Felzenzwalb I.I-shark-cartilage enamalungiselelo ikhusela iiseli ngokuchasene ne-hydrogen peroxide eyenze umonakalo kunye ne-mutagenesis. IMutat Res 1996; 367: 204-8. Jonga i-abstract.
77. UMathews J. Imithombo yeendaba ityisa isiphithiphithi kwi-shark cartilage njengonyango lomhlaza. J Natl Cancer Inst 1993; 85: 1190-1 (PubMed) (Umnqamlezo) Jonga i-abstract.
78. UBhargava P, uTrocky N, uMarshall J, et al. Inqanaba I ukhuseleko, ukunyamezelana kunye nesifundo se-pharmacokinetic sonyuka ngethamo, ukunyuka kwexesha lokunyuswa okuqhubekayo kweMSI-1256F (squalamine Lactate) kwizigulana ezinomhlaza ophambili. I-Proc Am Soc Clinical Oncol 1999; 18: A698.
79. UKalidas M, uHammond LA, uPatnaik P, et al. Isigaba I kunye nesifundo se-pharmacokinetic (PK) se-angiogenesis inhibitor, squalamine lactate (MSI-1256F). Ikliniki ye-Proc Am Soc Oncol 2000; 19: A698.
80. UPatnaik A, uRowinsky E, uHammond L, et al. Isigaba I kunye nesifundo se-pharmacokinetic (PK) se-angiogenesis inhibitor, squalamine lactate (MSI-1256F). I-Proc Am Soc Clinical Oncol 1999; 18: A622.
81. U-Evans WK, uLatreille J, uBatist G, et al. I-AE-941, i-inhibitor ye-angiogenesis: ingqiqo yophuhliso ngokudibanisa ne-induction chemotherapy / radiotherapy kwizigulana ezinomhlaza wesifo somhlaza wamaphaphu (NSCLC). Iklinikhi ye-Proc Am Soc Oncol 1999; 18: A1938.
82. URosenbluth RJ, uJennis AA, uCantwell S, uDeVries J. Oral u-shark cartilage kunyango lwezigulana ezinezilonda zobuchopho eziphambili. Isifundo somqhubi wenqanaba II. Iklinikhi ye-Proc Am Soc Oncol 1999; 18: A554.
83. ILeitner SP, iRothkopf MM, iHaverstick L, et al. Izifundo ezibini zesigaba sesibini somlomo owomileyo we-shark cartilage powder (i-SCP) kwizigulana (iipts) ezinesifuba se-metastatic okanye somhlaza wesibeletho esinganyangeki kunyango oluqhelekileyo. I-Proc Am Soc Clinical Oncol 1998; 17: A240.
84. IZiko loMhlaza weNatl CancerNet. I-Cartilage iwebhusayithi: www.cancer.gov (Ifumaneka nge-18 Agasti 2000).
85. I-Berbari P, i-Thibodeau A, i-Germain L, kunye ne-antiangiogenic yeziphumo zolawulo lomlomo lwe-cartilage ekhutshwayo ebantwini. I-J Surg Res 1999; 87: 108-13. Jonga i-abstract.
86. IHillman JD, iPeng AT, iGilliam AC, iRemick SC. Unyango lwe-Kaposi Sarcoma ngolawulo lomlomo lwe-shark cartilage kwi-Human Herpes virus 8-seropositive, Human Immunodeficiency Virus-Seronegative gay sex man. IArch Dermatol 2001; 137: 1149-52. Jonga i-abstract.
87. Uvavanyo lweklinikhi lwe-Neovastat. Iboniswe kuMbutho waseMelika woPhando lweCancer 92nd kwintlanganiso yonyaka. Ngomhla wamashumi amabini anesixhenxe ku-Matshi 2001.
88. UWilson JL. Imixholo ye-shark cartilage yoyisa i-psoriasis: uphononongo lophando kunye neziphumo zokuqala zeklinikhi. Enye into yokuGqibezela iTher 2000; 6: 291.
89. UMiller DR, uAnderson GT, uStark JJ, et al. Isigaba se-I / II sovavanyo lokhuseleko kunye nokusebenza kwe-shark cartilage kunyango lomhlaza ophambili. J Ikliniki yase-Oncol 1998; 16: 3649-55. Jonga i-abstract.
90. Umgaqo we-IW, uComac L. Shark akawufumani umhlaza. ISixeko saseGadi, i-NY: Iqela le-Avery yoPapasho; Ngo-1992.
91. Hunt TJ, Connelly JF. I-shark cartilage kunyango lomhlaza. NdinguJ J Health Syst Pharm 1995; 52: 1756-60. Jonga i-abstract.
92. U-Ashar B, u-Vargo E. Shark u-hepatitis [unobumba] obangelwa yintlala. UAnn Intern Med 1996; 125: 780-1. Jonga i-abstract.

Ukuhlaziywa okokugqibela-03/14/2019